Citigroup
CYTO

Citigroup’s Altamira Therapeutics Ltd CYTO Stock Holding History

Citigroup’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-154
Closed -$3.94K – 5809
2023
Q1 		$3.94K Buy
+154
New +$8.85K ﹤0.01% 4992
2016
Q4 		– Hold
0
– -$3K – 7365
2016
Q3 		– Hold
0
– – – 6886
2016
Q2 		– Hold
0
– – – 6654
2016
Q1 		– Hold
0
– – – 6923

Other funds holding CYTO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SCA
Stonebridge Capital Advisors St Paul, Minnesota $1.43B AUM 21.98% 1-Year Est. Return

Citigroup's CYTO Position: Q2 2023 in Review

Citigroup sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2023, closing a stake of 154 shares — an estimated $3.94K sold.

Citigroup first reported a position in CYTO in Q1 2023 and held it in 1 quarter. The position peaked at $3.94K in Q1 2023. 5 funds tracked by Wall St. Rank hold CYTO as of Q2 2023.

  • Citigroup reported no remaining Altamira Therapeutics Ltd position as of Q2 2023 after selling out during the quarter.
  • Citigroup sold 154 Altamira Therapeutics Ltd shares in Q2 2023, an estimated $3.94K.
  • Citigroup first reported a position in Altamira Therapeutics Ltd in Q1 2023 and held it in 1 quarter.
  • Citigroup's Altamira Therapeutics Ltd position peaked at $3.94K in Q1 2023.
  • 5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.